In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody drug conjugate (ADC) therapy for solid tumors.
Northbrook, IL 60062 -- (SBWIRE) -- 11/20/2023 -- The Antibody Drug Conjugates (ADC) industry represents a cutting-edge and rapidly evolving sector within the field of biopharmaceuticals. ADCs are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering highly targeted treatment to cancer cells while sparing healthy tissue. Over recent years, the ADC industry has witnessed substantial growth, driven by advancements in antibody engineering, linker technology, and payload selection, resulting in a robust pipeline of promising ADC candidates across various cancer types. With several ADCs already approved by regulatory agencies and many more in clinical development, the industry holds significant promise for improving the treatment landscape for cancer patients, offering the potential for enhanced efficacy and reduced side effects compared to traditional chemotherapy. As research and development efforts continue to expand, the ADC industry is poised to make substantial contributions to the future of oncology and personalized medicine.
Antibody Drug Conjugates (ADC) Market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.
The major factors driving the growth of the market are collaborations & partnerships among market players operating in the market, increasing focus on the development of new ADCs and frequent approval from the FDA for new ADCs. Robust products under clinical studies and increased use of ADCs as combination therapy are likely to uplift market growth in coming years.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857391
Browse in-depth TOC on "Antibody Drug Conjugates (ADC) Market"
260 - Tables
43 - Figures
283 – Pages
The Kadcyla segment dominated the market in 2022.
Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. In 2022, the Kadcyla held a dominant share owing to rise in the prevalence of cancer and increased use of ADCs for the treatment of cancer, which is one of the major factors driving the segmental growth. Furthermore, increased approvals for various disease indications for adcertis are likely to drive segmental growth in coming years.
The breast cancer segment accounted for the largest share of the disease type segment in the antibody drug
conjugates market in 2022.
The breast cancer segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed increasing prevalence of breast cancer across the globe. The launch of biosimilars is further likely to have a positive impact on segmental growth. For instance, in May 2021, Zydus launched Ujvira, the first antibody drug conjugate (ADC) biosimilar for treating both early and advanced HER2-positive breast cancer.
The Asia Pacific region will be the fastest-growing region of the antibody drug conjugates market in 2022.
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the antibody drug conjugates markets in the region is driven by a rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of ADCs among the patent population. The rising prevalence of cancer and increased investment in research & development of the launch of novel ADCs in the region are some of the major factors anticipated to upsurge the market growth.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857391
Antibody Drug Conjugates (ADC) Market Dynamics:
1. Rising incidence of cancer
2. Increasing investments for ADC development
3. Growing number of ADCs in clinical trials
4. Favorable regulatory support
1. High manufacturing costs
2. Side effects associated with ADCs
3. High attrition rate in product development
1. Adoption of combination therapies
2. High growth in emerging economies
3. Emergence of advanced ADCs
1. Technical complexities
Key Market Players of Antibody Drug Conjugates Industry:
The antibody drug conjugates market is competitive, with a small number of players competing for market shares.
F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), and Zydus Group (India), among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
- In July 2023, ImmunoGen, Inc., entered into a multi-target license and option agreement with ImmunoBiochem to develop next-generation antibody-drug conjugates.
- In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody drug conjugate (ADC) therapy for solid tumors.
- In June 2023, Lonza acquired Synaffix B.V. a biotechnology company involved in commercializing clinical-stage technology platforms for the development of antibody drug conjugates.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857391
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062